BARCELONA, Spain — A subgroup analysis of the DAVIO 2 trial showed that eyes implanted with the EYP-1901 intravitreal insert maintained stable visual acuity with strong anatomic control over 8 months, according to a presenter.
“EYP-1901 (EyePoint Pharmaceuticals) is a combination of vorolanib, which is a potent tyrosine kinase receptor inhibitor, and Durasert E, which is a bioerodible device that allows release of the drug for at least 6 months,” Giovanni Staurenghi, MD, said at the Euretina congress.
The trial compared EYP-1901 vs. aflibercept in patients with wet age-related